Active-ingredient Dossier

Empagliflozin

Active-ingredient Dossier for Empagliflozin (sodium-glucose cotransporter inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled…

Brand: JARDIANCE
Brand: GLYXAMBI
Brand: JARDIAMET
Therapeutic area: Endocrinology

What is

Empagliflozin Empagliflozin is a sodium-glucose cotransporter inhibitor.

Australian brands containing

Empagliflozin — JARDIANCE — GLYXAMBI — JARDIAMET

Therapeutic areas

Empagliflozin is registered in endocrinology (2 brands) and cardiology (1 brand).

Sponsor landscape

Boehringer Ingelheim markets empagliflozin in Australia.

PBS and regulatory activity

One brand containing empagliflozin has PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2024–25 fiscal year, empagliflozin products generated government expenditure of $105,911,172.68 across 2,034,950 scripts. The latest PBAC outcome was 1 May 2025, with 2 brands having PBAC outcomes on record. The latest AusPAR was 6 February 2024, with 1 brand having an AusPAR on record.